Wall Street analysts expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) to report $4.83 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Opiant Pharmaceuticals’ earnings. The lowest sales estimate is $4.10 million and the highest is $5.55 million. Opiant Pharmaceuticals reported sales of $4.37 million during the same quarter last year, which indicates a positive year-over-year growth rate of 10.5%. The firm is expected to issue its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Opiant Pharmaceuticals will report full year sales of $28.26 million for the current year, with estimates ranging from $18.60 million to $37.91 million. For the next financial year, analysts anticipate that the company will report sales of $31.53 million, with estimates ranging from $23.05 million to $40.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Opiant Pharmaceuticals.
Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.86. Opiant Pharmaceuticals had a negative return on equity of 12.82% and a negative net margin of 11.78%. The company had revenue of $6.78 million for the quarter, compared to analyst estimates of $3.91 million.
OPNT traded down $0.76 on Thursday, hitting $14.62. The company had a trading volume of 42,977 shares, compared to its average volume of 21,249. The stock has a fifty day moving average price of $13.11 and a 200-day moving average price of $13.13. Opiant Pharmaceuticals has a 12-month low of $9.98 and a 12-month high of $29.55. The stock has a market capitalization of $61.04 million, a price-to-earnings ratio of -2.06 and a beta of 0.43.
In other news, insider Phil Skolnick sold 10,000 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $13.19, for a total transaction of $131,900.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 30,000 shares of company stock worth $365,000 in the last 90 days. Insiders own 30.88% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Advisor Group Inc. boosted its position in Opiant Pharmaceuticals by 24.3% in the second quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock valued at $61,000 after buying an additional 900 shares during the last quarter. Northern Trust Corp boosted its position in Opiant Pharmaceuticals by 3.5% in the fourth quarter. Northern Trust Corp now owns 41,803 shares of the technology company’s stock valued at $604,000 after buying an additional 1,398 shares during the last quarter. Spark Investment Management LLC boosted its position in Opiant Pharmaceuticals by 17.6% in the first quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock valued at $198,000 after buying an additional 2,265 shares during the last quarter. BlackRock Inc. boosted its position in Opiant Pharmaceuticals by 44.0% in the fourth quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock valued at $149,000 after buying an additional 3,137 shares during the last quarter. Finally, Morgan Stanley boosted its position in Opiant Pharmaceuticals by 1,000.3% in the second quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock valued at $297,000 after buying an additional 20,377 shares during the last quarter. Hedge funds and other institutional investors own 18.60% of the company’s stock.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.